Abstract TC-01: Baby-TAM Impact on disease progression

Abstract Professor Hall will have reviewed his studies on the impact of lower doses of tamoxifen on changes in breast density, an important risk factor. Here I will review the work of Professor Decensi’s team on the ability of 5mg/d of tamoxifen (baby-Tam) on the progression rate of DCIS (69%) and other intraepithelial lesions (11% LCIS, 20% atypical ductal hyperplasia). This trial involved 500 pre- and postmenopausal women randomized equally between baby-Tam and placebo with a 9.7 year median follow up. All breast cancer progression (invasive (77%) and DCIS (23%)) was reduced by 42% (25 vs 41 events, P = 0.03) and contralateral tumours by 64% (6 vs 16 events, P = 0.025). No significant increase was seen in any side effect (Table). I will also briefly discuss their new award for a project to compare baby Tam to baby exemestane in a randomized trial in a similar population as above, initially for side effects, but also subsequently for efficacy. Professor Hall will have reviewed his studies on the impact of lower doses of tamoxifen on changes in breast density, an important risk factor. Here I will review the work of Professor Decensi’s team on the ability of 5mg/d of tamoxifen (baby-Tam) on the progression rate of DCIS (69%) and other intraepithelial lesions (11% LCIS, 20% atypical ductal hyperplasia). This trial involved 500 pre- and postmenopausal women randomized equally between baby-Tam and placebo with a 9.7 year median follow up. All breast cancer progression (invasive (77%) and DCIS (23%)) was reduced by 42% (25 vs 41 events, P = 0.03) and contralateral tumours by 64% (6 vs 16 events, P = 0.025). No significant increase was seen in any side effect (Table). I will also briefly discuss their new award for a project to compare baby Tam to baby exemestane in a randomized trial in a similar population as above, initially for side effects, but also subsequently for efficacy. Citation Format: J. Cuzick, P. Hall. Baby-TAM Impact on disease progression abstract. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr TC-01.